Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

By Bhanvi Satija (Reuters) -Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Johnson & Johnson's Rybrevant and Lazcluze combination shows significant overall survival benefits over Tagrisso in the ...

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...